The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
992
January 19, 1997
View Complete Issue         Table of Contents 2019 
Irinotecan for Metastatic Colorectal Cancer
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Irinotecan for Metastatic Colorectal Cancer
January 19, 1997 (Issue: 992)
Irinotecan hydrochloride (Camptosar - Pharmacia & Upjohn; formerly CPT-11) has been approved by the US Food and Drug Administration for treatment of metastatic colorectal cancer refractory to other drugs including fluorouracil (5-FU; Adrucil and...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Irinotecan for Metastatic Colorectal Cancer
Article code: 992c
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.